Atea Pharmaceuticals在Croi 2026公布临床前结果,支持首创药物AT-587治疗戊型肝炎病毒的潜力

美股速递
Feb 24

Atea Pharmaceuticals, Inc. (简称:Atea) 在近期举行的Croi 2026会议上,公布了其候选药物AT-587针对戊型肝炎病毒(HEV)的临床前研究数据。这些结果充分展示了AT-587作为同类首创疗法的巨大潜力。

临床前研究数据显示,AT-587在体外和体内模型中均表现出强大的抗病毒活性,能有效抑制HEV的复制。该药物通过一种新颖的作用机制靶向病毒,为其作为潜在的一线治疗方案提供了有力支持。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10